

Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice

Ewa Poleszak, Sylwia Wośko, Karolina Sławińska, Elżbieta Wyska, Aleksandra Szopa, Jan Sobczyński, Andrzej Wróbel, Urszula Doboszewska, Piotr Wlaź, Aleksandra Wlaź, Jarosław Szponar, Piotr Skałecki, Anna Serefko

PII:	S0166-4328(19)31189-1			
DOI:	https://doi.org/10.1016/j.bbr.2019.112297			
Reference:	BBR 112297			
To appear in:	Behavioural Brain Research			
Received Date:	31 July 2019			
Revised Date:	8 October 2019			
Accepted Date:	9 October 2019			

Please cite this article as: Poleszak E, Wośko S, Sławińska K, Wyska E, Szopa A, Sobczyński J, Wróbel A, Doboszewska U, Wlaź P, Wlaź A, Szponar J, Skałecki P, Serefko A, Ligands of the CB2 cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice, *Behavioural Brain Research* (2019), doi: https://doi.org/10.1016/j.bbr.2019.112297

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2019 Published by Elsevier.

Ligands of the CB₂ cannabinoid receptors augment activity of the conventional antidepressant drugs in the behavioural tests in mice

Ewa Poleszak ^{a,*}, Sylwia Wośko ^a, Karolina Sławińska ^a, Elżbieta Wyska ^b, Aleksandra Szopa^a, Jan Sobczyński^a, Andrzej Wróbel^c, Urszula Doboszewska^d, Piotr Wlaź ^d, Aleksandra Wlaź ^e, Jarosław Szponar^f, Piotr Skałecki^g, Anna Serefko ^{a,*}

^aChair and Department of Applied and Social Pharmacy, Medical University of Lublin, Chodźki 1, 20-093, Lublin, Poland

^bDepartment of Pharmacokinetics and Physical Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688, Kraków, Poland

^cSecond Department of Gynecology, Medical University of Lublin, Jaczewskiego 8, 20-090 Lublin, Poland

^dDepartment of Animal Physiology and Pharmacology, Institute of Biological Sciences, Maria Curie-Skłodowska University, Akademicka 19, 20-033, Lublin, Poland

^eDepartment of Pathophysiology, Medical University of Lublin, Jaczewskiego 8, 20-090, Lublin, Poland

^fToxicology Clinic, Medical University of Lublin: Clinical Department of Toxicology and Cardiology, Stefan Wyszyński Regional Specialist Hospital in Lublin, Al. Kraśnicka 100, Lublin, Poland

^gDepartment of Commodity Science and Processing of Raw Animal Materials, University of Life Sciences, Akademicka 13, 20-950 Lublin, Poland

*Corresponding authors:

Anna Serefko, e-mail address: anna.serefko@umlub.pl

Ewa Poleszak, e-mail address: ewa.poleszak@umlub.pl

Highlights

- JWH133 increases activity of conventional antidepressant drugs
- AM630 potentiates activity of conventional antidepressant drugs
- Interplay between CB₂ receptor ligands and antidepressants is pharmacodynamic in nature

Abstract

Although a lot of information can be found on the specific dual role of the endocannabinoid system in the emotional-related responses, little is known whether stimulation or inhibition of the CB receptors may affect the activity of the frequently prescribed antidepressant drugs. Our interests have been particularly focused on the potential influence of the CB₂ receptors, as the ones whose central effects are relatively poorly documented when compared to the central effects of the CB₁ receptors. Therefore, we evaluated the potential interaction between the CB₂ receptor ligands (i.e., JWH133 - CB₂ receptor agonist and AM630 - CB₂ receptor inverse agonist) and several common antidepressant drugs that influence the monoaminergic system (i.e., imipramine, escitalopram, reboxetine). In order to assess the antidepressant-like effects we used two widely recognized behavioural tests, the mouse forced swim test (FST) and the tail suspension test (TST). Brain concentrations of the tested antidepressants were evaluated by the HPLC method. Intraperitoneal co-administration of per se ineffective doses of JWH133 (0.25 mg/kg) or AM630 (0.25 mg/kg) with imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) significantly shortened the immobility time of mice in the FST and the TST, whereas it did not disturb their spontaneous locomotor activity. Furthermore, the brain levels of antidepressants were not changed. Summarizing, the results of the present study revealed that both activation and inhibition of the CB₂ receptor function have a potential to strengthen the antidepressant activity of drugs targeting the monoaminergic system. Most probably, the described interaction has a pharmacodynamic background.

Keywords: JWH133, AM630, imipramine, reboxetine, escitalopram, antidepressant activity

1. Introduction

The endocannabinoid system has attracted clinicians attention for decades as an endogenous homeostatic system associated with a large number of neurotransmitters and their pathways, and implicated in numerous physiological functions, including an inflammatory process, pain, or emotions. The endocannabinoid system consists of the endogenous arachidonate-based lipids referred to as "endocannabinoids" (such as anandamide and 2-arachidonoylglycerol), enzymes responsible for their synthesis (N-acylphosphatidylethanolamine-phospholipase D and diacylglycerol lipase) and degradation (fatty acid amide hydrolase and monoacylglycerol lipase), and the endocannabinoid CB receptors (for review see [1,2]). Thus far, two types of typical CB receptors, encoded by CNR1 and CNR2 genes, have been described. Both CB₁ and

CB₂ receptors bind endogenous and exogenous cannabinoids with high affinity. Due to specific mechanism of action of CB receptors, on the one hand the endocannabinoid system can help to restore the brain balance after exposure to different stressors, but on the other hand, it is involved in the pathogenesis of certain mental disturbances, like anxiety, stress, aggressive behavior, or depression. Until recently, only CB₁ receptors were thought to be implicated in the development of mental diseases as the ones that are expressed both in the periphery and the brain. CB₂ receptors were mainly considered as the peripheral receptors. It was believed that they were distributed almost exclusively within the immune cells and thus, that they have only the immunomodulatory role (i.e., regulation of cytokines or migration of immune cells) (for review see [1-3]). However, several research team have found out that CB₂ receptors are also localized in the rodent [4] and human central nervous system [5-7]. At first, their presence in the brain was linked to existence of pathological conditions, like Alzheimer's disease [8], multiple sclerosis, amyotrophic lateral sclerosis [9], or tumours [10], but then, they were also identified under physiological conditions [5]. CB₂ receptors are localized in the spinal nucleus, olfactory nucleus, thalamus, hippocampus, amygdala, cerebral cortex, and cerebellum [11,12]. They are mainly distributed post-synaptically, but they can also be found in the presynaptic areas. Functional effects of CB2 receptors that prove their presence in the brain have also been described in literature. It has been revealed that CB₂ receptors are involved in the inflammatory responses that accompany the neurodegenerative processes [8], in stress-induced neuroinflammation [13], schizophrenia, alcohol preference in mice, alcoholism in humans [14], drug abuse, motor function, and emotionality [4]. Onaivi et al. [4] reported a reduced expression of CB₂ receptors in the striatum and midbrain of mice that developed alcohol preference.

Involvement of CB₂ receptors in the development of depression has also been suggested. Deletion of CB₂ receptors in mice with C57BL/6J congenic background induced depression-like behavior in the TST [15], whereas genetically-induced lowered CB₂ receptor function (in the *Cnr2* heterozygote knock-out mice) was associated with an increased susceptibility to depression when exposed to immune or emotional stressors (i.e., poly I:C or chronic mild stress, respectively) [16]. Reduction of CB₂ receptors in the hippocampus was observed in mice that had been subjected to the chronic unpredictable mild stress [17]. In turn, García-Gutiérrez et al. [17] found out that the genetically-induced overexpression of the CB₂ receptors exerted an antidepressant-like effects in the TST and the novelty-suppressed feeding test in mice with swiss ICR congenic background. Moreover, these animals presented a higher level of the brain-derived neurotrophic factor (BDNF) in the hippocampus and they were

resistant to stressful depressogenic-like situations in the chronic unpredictable mild stress model. Both stimulation of CB₂ receptors by their selective agonists (GW405833, JWH133, or β -caryophyllene) [18-20] as well as inhibition by their selective inverse agonist (AM630) [17,20] produced an antidepressant-like activity in the FST and/or the TST in naïve albino Swiss [20], C57BL/6 [19], ICR Swiss [17] mice, or in rats that underwent chronic constriction injury [18]. Additionally, treatment with CB₂ ligands inhibited the development of the depressive-like behaviour in mice [17] and rats [21] subjected to the chronic unpredictable stress. Ishiguro et al. [14] suspected association between genetic variants of the CB₂ gene and depression in Japanese people.

Although a lot of information can be found on the specific dual role of the endocannabinoid system in the emotional-related responses, little is known whether stimulation or inhibition of CB receptors may affect the activity of the frequently prescribed antidepressant drugs. This subject seems to be quite important, in the view of the fact that more than 322 million people suffer from depression and that the efficacy of available drugs is not satisfactory. Hence, new (even controversial) treatment options are necessary. Our interests have been particularly focused on the potential influence of the CB₂ receptors, as the ones whose central effects are relatively poorly documented when compared to the central effects of the CB1 receptors. For this purpose, we evaluated the potential interaction between CB₂ receptor ligands (i.e., JWH133 – CB₂ receptor agonist and AM630 – CB₂ receptor inverse agonist) and three common antidepressant drugs that influence the monoaminergic system (i.e., imipramine – a tricyclic antidepressant, escitalopram – a selective serotonin reuptake inhibitor, and reboxetine – a selective noradrenaline reuptake inhibitor). According to the literature data [22], JWH133 has a very high affinity towards CB₂ receptors (i.e., Ki = 3.4 ± 1 nM) and exhibits 200-fold selectivity for them over CB₁ receptors. AM630 also binds selectively to CB₂ receptors, with a CB₂/CB₁ affinity ratio of 165 and Ki = 31.2 nM at the CB₂ receptor [23]. Being an inverse agonist of CB2 receptors, AM630 has both affinity towards CB₂ receptors and negative intrinsic activity. It binds to the constitutively activated receptors and decreases their activity below the basal level [24]. Thus, AM630 acts oppositely to JWH133. In order to assess the antidepressant-like effects we used two widely recognized behavioural tests, the mouse FST and the TST.

2. Materials and methods

2.1. Animals

The experiments were carried out on male Albino Swiss mice (25-30 g). Animals were maintained in standard cages (8 mice/cage) placed in environmentally controlled rooms (humidity ca. 45-55%, temperature of 22-23 °C, 12 h light/dark cycle). They were given water and food *ad libitum*. All performed procedures were planned in accordance with binding law related to the experimental studies on animal models, and they were approved by the Local Ethics Committee.

2.2. Drug administration

JWH133 ((6aR,10aR)-3-(1,1-Dimethylbutyl)-6a,7,10,10a-tetrahydro-6,6,9-trimethyl-6Hdibenzo[b,d]pyran, 0.25 mg/kg, Tocris) and AM630 (6-Iodo-2-methyl-1-[2-(4morpholinyl)ethyl]-1H-indol-3-yl](4-methoxyphenyl)methanone, 0.25 mg/kg, Tocris) were suspended in Tween 80 solution (1%). Imipramine hydrochloride (15 mg/kg, Sigma-Aldrich), escitalopram oxalate (2 mg/kg, Sigma-Aldrich), and reboxetine mesylate (2.5 mg/kg, Abcam Biochemicals) were dissolved in physiological saline. The tested suspensions/solutions were administered intraperitoneally (*ip*): imipramine, escitalopram, and reboxetine were given 60 min before behavioural tests, whereas JWH133 and AM630 were given 30 min before behavioural tests. The pretreatment schedules and doses were selected on the basis of the literature data [25] and were confirmed in the preliminary tests carried out in our lab. The control mice received *ip* injections of vehicles.

2.3. Forced swim test (FST)

The FST was performed according to method that we used before [26]. Each mouse was placed individually into glass cylinders (height 25 cm, diameter 10 cm) containing 10 cm of water at 23–25 °C and it was left there for 6 min. The immobility time of animals was recorded between the 2nd and the 6th min of the test. A given mouse was judged immobile when it stopped struggling and remained floating motionless in the water. Movements necessary to keep animal's head above the water level were acceptable.

2.4. Tail suspension test (TST)

The TST was performed according to the method that we used before [27]. Each mouse was suspended by the tail (2 cm from the end of the tail) using adhesive tape and it was left hanging for 6 min. Though the immobility time in the TST can be measured for the whole duration of the test, we recorded the activity of animals for the last 4 min. Similarly to the situation observed in the FST, animals at the beginning of the TST usually show an increased

escape-oriented struggling, which lasts ca. 1-2 min [28]. In order to avoid potential confounding of the results, the first 2 min of the test was treated as a habituation period. A given mouse was judged immobile when it stopped moving its body and limbs. Only movements necessary to breathe were acceptable.

2.5. Spontaneous locomotor activity

Spontaneous locomotor activity was measured automatically, as was described before [26]. We used an activity meter Opto-Varimex-4 Auto-Track (Columbus Instruments, USA) that contains plexiglas cages with lids $(43 \times 43 \times 32 \text{ cm})$ equipped with a set of four infrared emitters and four detectors monitoring mice movements. Each animal was placed individually in the cage. A distance travelled by a given animal was recorded between the 2nd and the 6th min of the test. This time interval corresponded with the one analyzed in the TST and the FST.

2.6. Determination of the antidepressant levels in brain homogenates

New cohorts of animals were used for the biochemical studies. The tested mice were decapitated 60 min after injection of the antidepressant drug (with or without JWH133 or AM630). Their brains were dissected and frozen. Imipramine, desipramine (i.e., an active metabolite of imipramine), escitalopram, and reboxetine brain levels were determined with use of the high-performance liquid chromatography (HPLC) method, as was described before [26]. The assays were reproducible with low intra- and interday variation (coefficient of variation <10%). The extraction efficiencies of the analyzed compounds and the internal standard ranged from 66% to 95%. Concentrations of antidepressants were expressed for the wet brain tissue in ng/g.

2.7. Statistical analysis

t-test or two-way analysis of variance (ANOVA) followed by Bonferroni's *post-hoc* test were applied, depending on the experimental design. The outcomes were given as the means \pm standard error of the mean (SEM). When p < 0.05, differences between the compared groups were treated as significant.

3. Results

3.1. Effects of a concurrent administration of JWH133 and the tested antidepressants in the FST

A single administration of JWH133 (0.25 mg/kg) or a given antidepressant drug (i.e., imipramine – 15 mg/kg, escitalopram – 2 mg/kg, or reboxetine – 2.5 mg/kg) did not significantly influence the immobility time of animals in the FST. When the tested substances were injected in respective combinations, the treated mice were swimming for a longer time than their control counterparts (Fig. 1A). Two-way ANOVA presented: (1) a significant JWH133-imipramine interaction [F(1,28)=8.57; p=0.0067] with a significant effect of JWH133 [F(1,28)=10.24; p=0.0034] and a significant effect of imipramine [F(1,28)=23.14; p<0.0001], (2) a significant JWH133-escitalopram interaction [F(1,26)=4.95; p=0.0351] with a significant effect of JWH133 [F(1,26)=8.85; p=0.0063] and a significant effect of escitalopram [F(1,26)=22.22; p<0.0001], and (3) a significant JWH133-reboxetine interaction [F(1,28)=10.87; p=0.0027] with a significant effect of JWH133 [F(1,28)=12.89; p=0.0012] and a significant effect of reboxetine [F(1,28)=27.14; p<0.0001].

3.2. Effects of a concurrent administration of AM630 and the tested antidepressants in the FST

Concurrent administration of the sub-effective doses of AM630 (0.25 mg/kg) and the antidepressant drug (i.e., imipramine – 15 mg/kg, escitalopram – 2 mg/kg, or reboxetine – 2.5 mg/kg) increased activity of the tested mice in the FST, which was presented in Fig. 2A. Two-way ANOVA demonstrated: (1) a significant AM630-imipramine interaction [F(1,26)=4.34; p=0.0472] with a significant effect of AM630 [F(1,26)=11.98; p=0.0019] and a significant effect of imipramine [F(1,26)=15.29; p=0.0006], (2) a significant AM630-escitalopram interaction [F(1,24)=6.63; p=0.0166] with a significant effect of AM630 [F(1,24)=13.94; p=0.0010] and a significant effect of escitalopram [F(1,24)=12.42; p=0.0017], and (3) a significant AM630-reboxetine interaction [F(1,28)=7.79; p=0.0094] with a significant effect of AM630 [F(1,28)=10.14; p=0.0035] and a significant effect of reboxetine [F(1,28)=14.32; p=0.0007].

3.3. Effects of a concurrent administration of JWH133 and the tested antidepressants in the TST

Mice treated with a single injection of JWH133 (0.25 mg/kg) or a given antidepressant drug (i.e., imipramine -15 mg/kg, escitalopram -2 mg/kg, or reboxetine -2.5 mg/kg) stayed immobile for the same duration of time as the animals from the control group. However, when the tested substances were injected in respective combinations, the antidepressant-like effect was detected in the TST (Fig. 1B). The following significant drug-drug interactions were

revealed by two-way ANOVA analysis: (1) a significant JWH133-imipramine interaction [F(1,26)=4.73; p=0.0389] with a significant effect of JWH133 [F(1,26)=8.17; p=0.0083] and a significant effect of imipramine [F(1,26)=16.48; p=0.0004], (2) a significant JWH133-escitalopram interaction [F(1,28)=8.73; p=0.0063] with a significant effect of JWH133 [F(1,28)=12.82; p=0.0013] and a significant effect of escitalopram [F(1,26)=12.42; p=0.0015], and (3) a significant JWH133-reboxetine interaction [F(1,28)=5.56; p=0.0255] with a significant effect of JWH133 [F(1,28)=8.13; p=0.0081] and a significant effect of reboxetine [F(1,28)=16.25; p=0.0004].

3.4. Effects of a concurrent administration of AM630 and the tested antidepressants in the TST

After a single administration of AM630 (0.25 mg/kg) or a given antidepressant drug (i.e., imipramine – 15 mg/kg, escitalopram – 2 mg/kg, or reboxetine – 2.5 mg/kg), behavior of the treated mice in the TST was similar to the one observed for animals from the control group. By contrast, co-administration of AM630 with a given antidepressant drug significantly reduced the immobility time of animals (Fig. 2B). Two-way ANOVA demonstrated: (1) a significant AM630-imipramine interaction [F(1,28)=9.18; p=0.0052] with a significant effect of AM630 [F(1,28)=10.38; p=0.0019] and a significant effect of imipramine [F(1,28)=10.65; p=0.0029], (2) a significant AM630-escitalopram interaction [F(1,24)=4.60; p=0.0424] with a significant effect of AM630 [F(1,24)=6.28; p=0.0194] and a significant effect of escitalopram [F(1,24)=18.63; p=0.0002], and (3) a significant AM630-reboxetine interaction [F(1,28)=9.64; p=0.0043] with a significant effect of AM630 [F(1,28)=11.26; p=0.0023] and a significant effect of reboxetine [F(1,28)=25.20; p<0.0001].

3.5. Effects of a concurrent administration of JWH133 or AM630 and the tested antidepressants on the spontaneous locomotor activity of mice

As presented in Table 1, neither a single administration of the tested CB₂ receptor ligands or antidepressants nor their respective combinations influenced the spontaneous locomotor activity of animals.

3.6. Pharmacokinetic studies

Outcomes of the pharmacokinetic studies demonstrated that none of the tested cannabinoid CR_2 receptor ligands (i.e., JWH133 – 0.25 mg/kg or AM630 – 0.25 mg/kg) elevated the brain levels of imipramine, desipramine, escitalopram, and reboxetine (Table 2). *t*-test revealed the

following results: (1) t(14) = 1.276, p = 0.2226 for the JWH133-imipramine (15 mg/kg) combination, (2) t(14) = 0.6404, p = 0.5323 for the JWH133-desipramine combination, (3) t(18) = 0.7445, p = 0.4689 for the JWH133-escitalopram (2 mg/kg) combination, (4) t(14) = 0.1032, p = 0.9193 for the JWH133-reboxetine (2.5 mg/kg) combination, (5) t(14) = 0.3359, p = 0.7419 for the AM630-imipramine (15 mg/kg) combination, (6) t(14) = 0.1095, p = 0.9144 for the AM630-desipramine (an active metabolite of imipramine) combination, (7) t(14) = 0.8318, p = 0.4195 for the AM630-escitalopram (2 mg/kg) combination, and (8) t(14) = 0.005376, p = 0.9958 for the AM630-reboxetine (2.5 mg/kg) combination.

4. Discussion

In the course of intensive studies over the pathomechanism of depression, the endocannabinoid system has emerged as an important item in the development and/or treatment of this disease. Medical and scientific bases provide discrepant information on the cannabinoids effects in mood disorders. Both the pro- and antidepressant activity have been recorded after cannabis consumption, and these effects use to be attributed exclusively to CB₁ receptors. However, quite recently it has been proved that CB₂ receptors can also be found in different brain areas, including those responsible for emotions, like the prefrontal cortex, hippocampus, or amygdala [4,11,17,29]. Thus, CB₂ receptors seem to be also involved in mood changes in humans, though their impact is still relatively poorly documented. Several authors suggest that CB₂ receptors could be an interesting novel target for the treatment of depressive disorders, including the post-stroke depression [17,21].

The antidepressant potential of JWH133 (0.5-1 mg/kg) – the CB₂ receptor agonist applied in our study, was observed by Kruk-Słomka et al. [20] in the FST in Swiss mice. The authors demonstrated that the JWH133 treatment exerted the U-shaped anti-immobility pattern, with ineffectiveness of the lowest (0.25 mg/kg) and the highest (2 mg/kg) tested doses. As for the AM630 – the CB₂ receptor inverse agonist, results from the behavioural studies are controversial. In the above-mentioned experiments carried out by the team of Kruk-Słomka [20], only its lowest tested dose (i.e., 0.5 mg/kg) was effective in the FST, whereas the concentrations of 1-3 mg/kg did not increase the swimming time of animals. Quite contrary were the outcomes reported by García-Gutiérrez et al. [17] who demonstrated that an acute administration of 1-3 mg/kg of AM630 produced an antidepressant-like activity in the FST, but only in the wild type of swiss ICR mice; these doses did not change the behaviour of animals with experimentally-induced overexpression of the CB₂ receptors. In fact, the authors revealed that after an acute and chronic administration of AM630 different

effects in the biochemical and behavioural tests measuring the depression level in rodents may be recorded, depending on the applied experimental conditions. A 4-week administration of this CB₂ receptor ligand in the stressed wild-type ICR Swiss mice prevented the development of depression-like behaviour measured by the TST and by the sucrose intake test, whereas such a treatment had no impact on the behaviour of the non-stressed wild-type animals. Furthermore, the AM630 therapy *per se* did not influence the expression of the CB₂ receptor, BDNF gene, or the BDNF protein level in the hippocampus, but this CB₂ receptor ligand significantly reduced the BDNF loss and reversed the reduction in CB₂ receptor levels induced by the unpredictable chronic mild stress [17].

To our knowledge, the present study is the first one that assessed the influence of CB_2 receptor ligands on the activity of conventional antidepressant drugs that affect the monoaminergic system. We examined the impact of co-administration of CB₂ receptor agonist (JWH133) or CB₂ receptor antagonist (AM630) and imipramine (a tricyclic antidepressant), escitalopram (a selective serotonin reuptake inhibitor), or reboxetine (a selective inhibitor of noradrenalin reuptake) on the depression-related behaviour of mice in the FST and the TST, i.e. two most widely used animal tests evaluating the antidepressant-like activity. We demonstrated that JWH133 and AM630 when administered in per se inactive dose of 0.25 mg/kg significantly intensified the antidepressant effects of the applied drugs (also given at the sub-effective doses: 15 mg/kg of imipramine, 2 mg/kg of escitalopram, and 2.5 mg/kg of reboxetine), suggesting an addition or synergism of action. Mice that received single injections of respective combinations (imipramine-, escitalopram-, or reboxetine-CB₂ receptor ligand) were more mobile in the FST and the TST than animals from the control groups. According to the literature data [30,31] this observation can be treated as an indicator of the antidepressant behaviour. Similarly to our observations, both JWH133 and AM630 when given in a non-effective dose of 2 mg/kg significantly potentiated the antidepressant activity of an antagonist of the muscarinic acetylcholine receptors, i.e. scopolamine, in the FST in Swiss mice [20]. Though there are reports that CB₂ receptor agonists and antagonists may alter spontaneous locomotor activity of animals in a strain- and gender-dependent manner [4], we did not notice any differences in locomotion of mice from the tested and control groups. Similarly, in experiments by Kruk-Słomka et al. [20] no stimulant/inhibitory action of JWH133 (0.25-2 mg/kg) or AM630 (0.5-3 mg/kg) was noticed. Consequently, it is improbable that the antidepressant-like effects observed in the behavioural tests in the present study were false positive.

Generally, the molecular mechanism of the antidepressant-like activity of CB receptor ligands seems to be very complicated and complex. It has not been fully understood yet. Strangely enough, both CB1 and CB2 receptor agonists and antagonists may exert the antidepressant-like activity in rodents as well as they can induce the pro-depressive behaviour in animals. Moreover, it was found out that administration of the inactive dose of both CB₂ receptor antagonist (AM630, 2 mg/kg) and CB₁ antagonist (AM251, 0.25 mg/kg) is able to abolish the antidepressant-like effects of the active doses of CB₂ receptor agonist (JWH133, 0.5 and 1 mg/kg) in the FST in naïve Swiss mice. Similarly, in the same strain of rodents, administration of the non-effective dose of both CB₂ receptor antagonist (AM630, 2 mg/kg) and CB1 antagonist (AM251, 0.25 mg/kg) is able to reverse the antidepressant-like effects of the active doses of CB₁ receptor agonist (oleamide, 10 and 20 mg/kg) [20]. In fact, Onaivi et al. [4] noted that in different neuronal populations CB1 and CB2 receptors work to a certain point independently, but to a certain point also cooperatively in regulation of diverse physiological activities affected by cannabinoids. Viewing the above-mentioned, it should not be surprising that both JWH133 and AM630, i.e., the compounds that should act oppositely, potentiated the activity of the tested antidepressants in our study. Most probably, elevation of the serotonin and/or noradrenaline levels leading to potentiation of the serotonergic and/or noradrenergic neurotransmissions was responsible for the observed effects. Both the tested antidepressant drugs as well as cannabinoids are believed to modulate the monoaminergic system [32]. Franklin et al. [33] demonstrated that CB₂ receptors are implicated in the cannabinoid-induced upregulation of the serotonergic 5-HT_{2A} receptors in the brain. This effect is most probably mediated by internalization of CB₂ receptors and stimulation of the ERK1/2 signalling pathway. Disturbances in the 5-HT_{2A} receptor-dependent signalling are involved in the pathomechanism of different neuropsychiatric disorders, like schizophrenia, anxiety, or depression [34,35]. It is also possible that CB₂ receptors modulate the depressionrelated responses via alteration in immune system. Their increased expression in the brain was observed after an intra-striatal administration of lipopolysaccharide in a rat model of Parkinson's disease and it corresponded with an activation of the microglia [36]. In experiments by Zoppi and colleagues [13], activation of CB₂ receptors by experimentallyinduced overexpression or administration of an CB₂ receptor agonist in ICR Swiss mice exerted the anti-inflammatory or neuroprotective effects via control of glutamate uptake, whereas CB2 receptors knock-out potentiated stress-induced neuroinflammatory responses. A specific role of neuro-immune interactions in the development of psychiatric disorders has been examined for decades and a range of diverse studies have demonstrated a clear link

between chronic immune responses and occurrence of depression [37]. Stimulation of CB₂ receptors in the brain is also known to reduce expression of inducible nitric oxide synthase, production of nitric oxide, generation of reactive oxygen/nitrogen species, and thus, to attenuate the oxidative stress [38]. Additionally, neither JWH133 nor AM630 are exclusively specific for CB₂ receptors, but they are only CB₂ receptor-selective. They also exhibit partial affinity for CB₁ receptors [39,40]. Therefore, pathways connected with the CB₁ receptors may also contributed to the effects detected in our experiments.

Since the pharmacokinetic assays showed that neither JWH133 nor AM630 enhanced the brain levels of the tested antidepressant drugs (i.e., imipramine with its active metabolite – desipramine, escitalopram, or reboxetine), it should be assumed that the potentiation of the antidepressant effect observed in our study took place in the pharmacodynamic phase instead of in the pharmacokinetic one. However, based on the experiments of Smaga et al. [41], it is highly unlikely that an acute administration of the antidepressant drugs applied in our study might have changed the expression of endocannabinoid receptors (either CB₁ or CB₂) in the mouse brain. Such effects couldn't be ruled out after prolonged (14-day) treatment. Reduced levels of CB₁ and/or CB₂ receptors were detected in the dorsal striatum, nucleus accumbens, and/or cerebellum of male Wistar rats exposed to imipramine (15 mg/kg), whereas increased levels of CB₁ and/or CB₂ receptors in the hippocampus and/or prefrontal cortex with decreased levels of CB₁ receptors in dorsal striatum were recorded after escitalopram treatment (10 mg/kg) [41]. In the view of the above, further studies over the molecular mechanism of the interactions demonstrated in our experiments are needed.

5. Conclusions

The results of the present study revealed that both activation and inhibition of the CB₂ receptor function have a potential to strengthen the antidepressant activity of drugs targeting the monoaminergic system. Most probably, the described interaction has a pharmacodynamic background. Though our findings should be treated as the preliminary ones, we assume that the modulation of the endocannabinoid neurotransmission *via* CB₂ ligands could be a promising strategy as an adjuvant treatment in patients with depression. Such an approach could have additional benefits, since the CB₂ selective ligands are thought to be devoid of central nervous system side effects that may limit the clinical use of other substances with antidepressant potential [19].

6. Funding

This study was supported by Funds for Statutory Activity of the Medical University of Lublin, Poland. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

- M. Häring, S. Guggenhuber, B. Lutz, Neuronal populations mediating the effects of endocannabinoids on stress and emotionality, Neuroscience. 204 (2012) 145-158.
- [2] R.G. Pertwee (Ed.), Endocannabinoids, Handbook of Experimental Pharmacology, Springer International Publishing, Switzerland, 2015.
- [3] S. Zou, U. Kumar, 2018. Cannabinoid Receptors and the Endocannabinoid System: Signaling and Function in the Central Nervous System. Int. J. Mol. Sci. 19, e833.
- [4] E.S. Onaivi, H. Ishiguro, J.P. Gong, S. Patel, P.A. Meozzi, L. Myers, A. Perchuk, Z. Mora, P.A. Tagliaferro, E. Gardner, A. Brusco, B.E. Akinshola, B. Hope, J. Lujilde, T. Inada, S. Iwasaki, D. Macharia, L. Teasenfitz, T. Arinami, G.R. Uhl, 2008. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS. One. 20, e1640.
- [5] M.D. Van Sickle, M. Duncan, P.J. Kingsley, A. Mouihate, P. Urbani, K. Mackie, N. Stella, A. Makriyannis, D. Piomelli, J.S. Davison, L.J. Marnett, V. Di Marzo, Q.J. Pittman, K.D. Patel, K.A. Sharkey, Identification and functional characterization of brainstem cannabinoid CB2 receptors, Science. 310 (2005) 329-332.
- [6] J.C. Ashton, D. Friberg, C.L. Darlington, P.F. Smith, Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study, Neurosci. Lett. 396 (2006) 113-116.
- [7] M. Beltramo, N. Bernardini, R. Bertorelli, M. Campanella, E. Nicolussi, S. Fredduzzi, A. Reggiani, CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms, Eur. J.Neurosci. 23 (2006) 1530-1538.
- [8] C. Benito, E. Nunez, R.M. Tolon, E.J. Carrier, A. Rabano, C.J. Hillard, J. Romero, Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains, J.Neurosci. 23 (2003) 11136-11141.
- [9] Y. Yiangou, P. Facer, P. Durrenberger, I.P. Chessell, A. Naylor, C. Bountra, R.R. Banati, P. Anand, COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord, BMC. Neurol. 6 (2006) 12-16.
- [10] M. Guzman, C. Sanchez, I. Galve-Roperh, Control of the cell survival/death decision by cannabinoids, J. Mol. Med. (Berl.) 78 (2001) 613-625.

- [11] J.P. Gong, E.S. Onaivi, H. Ishiguro, Q.R. Liu, P.A. Tagliaferro, A. Brusco, G.R. Uhl, Cannabinoid CB2 receptors: immunohistochemical localization in rat brain, Brain. Res. 1071 (2006) 10-23.
- [12] E.S. Onaivi, H. Ishiguro, P. Sejal, P.A. Meozzi, L. Myers, P. Tagliaferro, B. Hope, C.M. Leonard, G.R. Uhl, A. Brusco, E. Gardner, Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression, Methods. Mol. Med. 123 (2006) 291-298.
- [13] S. Zoppi, J.L. Madrigal, J.R. Caso, M.S. Garcia-Gutierrez, J. Manzanares, J.C. Leza,
 B. Garcia-Bueno, Regulatory role of the cannabinoid CB2 receptor in stress-induced neuroinflammation in mice, Br. J.Pharmacol. 171 (2014) 2814-2826.
- [14] H. Ishiguro, S. Iwasaki, L. Teasenfitz, S. Higuchi, Y. Horiuchi, T. Saito, T. Arinami, E.S. Onaivi, Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans, Pharmacogenomics. J. 7 (2007) 380-385.
- [15] A. Ortega-Alvaro, A. Aracil-Fernandez, M.S. Garcia-Gutierrez, F. Navarrete, J. Manzanares, Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice, Neuropsychopharmacology. 36 (2011) 1489-1504.
- [16] H. Ishiguro, Y. Horiuchi, K. Tabata, Q.R. Liu, T. Arinami, E.S. Onaivi, 2018.Cannabinoid CB2 Receptor Gene and Environmental Interaction in the Development of Psychiatric Disorders. Molecules. 23, e1836.
- [17] M.S. Garcia-Gutierrez, J.M. Perez-Ortiz, A. Gutierrez-Adan, J. Manzanares, Depression-resistant endophenotype in mice overexpressing cannabinoid CB(2) receptors, Br. J. Pharmacol. 160 (2010) 1773-1784.
- [18] B. Hu, H. Doods, R.D. Treede, A. Ceci, Depression-like behaviour in rats with mononeuropathy is reduced by the CB2-selective agonist GW405833, Pain. 143 (2009) 206-212.
- [19] A. Bahi, S. AlMansouri, E. Al Memari, M. Al Ameri, S.M. Nurulain, S. Ojha, β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice, Physiol.Behav. 135 (2014) 119-124.
- [20] M. Kruk-Slomka, A. Michalak, G. Biala, Antidepressant-like effects of the cannabinoid receptor ligands in the forced swimming test in mice: mechanism of action and possible interactions with cholinergic system, Behav. Brain. Res. 284 (2015) 24-36.
- [21] S. Wang, H. Sun, S. Liu, T. Wang, J. Guan, J. Jia, Role of hypothalamic cannabinoid receptors in post-stroke depression in rats, Brain. Res. Bull. 121 (2016) 91-97.

- [22] J.W. Huffman, S.A. Hepburn, N. Lyutenko, A.L.S. Thompson, J.L. Wiley, D.E. Selley, B.R. Martin, 1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-Δ8-tetrahydrocannabinols: New Selective Ligands for the Cannabinoid CB2 Receptor, Bioorg. Med. Chem. 18 (2010) 7809-7815.
- [23] R.A. Ross, H.C. Brockie, L.A. Stevenson, V.L. Murphy, F. Templeton, A. Makriyannis, R.G. Pertwee, Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630, Br. J.Pharmacol. 126 (1999) 665-672.
- [24] K.A. Berg, W.P. Clarke, Making Sense of Pharmacology: Inverse Agonism and Functional Selectivity, Int. J.Neuropsychopharmacol. 21 (2018) 962-977.
- [25] M. Kruk-Slomka, I. Banaszkiewicz, G. Biala, The Impact of CB2 Receptor Ligands on the MK-801-Induced Hyperactivity in Mice, Neurotox. Res. 31 (2017) 410-420.
- [26] E. Poleszak, W. Stasiuk, A. Szopa, E. Wyska, A. Serefko, A. Oniszczuk, S. Wosko, K. Swiader, P. Wlaz, Traxoprodil, a selective antagonist of the NR2B subunit of the NMDA receptor, potentiates the antidepressant-like effects of certain antidepressant drugs in the forced swim test in mice, Metab. Brain. Dis. 31 (2016a) 803-814.
- [27] E. Poleszak, A. Szopa, E. Wyska, W. Kukula-Koch, A. Serefko, S. Wosko, K. Bogatko, A. Wrobel, P. Wlaz, Caffeine augments the antidepressant-like activity of mianserin and agomelatine in forced swim and tail suspension tests in mice, Pharmacol. Rep. 68 (2016b) 56-61.
- [28] Q. Chang, S. Szegedi, J. O'Connor, R. Dantzer, K. Kelley, Cytokine-Induced Sickness Behavior and Depression, in: A. Siegel, S.S. Zalcman(Eds.), The Neuroimmunological Basis of Behavior and Mental Disorders, Springer, Boston, MA, 2009, pp. 145-181.
- [29] F.S. den Boon, P. Chameau, Q. Schaafsma-Zhao, W. van Aken, M. Bari, S. Oddi, C.G. Kruse, M. Maccarrone, W.J. Wadman, T.R. Werkman, Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors, Proc. Natl. Acad. Sci. U. S. A. 109 (2012) 3534-3539.
- [30] R.D. Porsolt, A. Bertin, M. Jalfre, Behavioral despair in mice: a primary screening test for antidepressants, Arch. Int.Pharmacodyn.Ther. 229 (1977) 327-336.
- [31] L. Steru, R. Chermat, B. Thierry, P. Simon, The tail suspension test: a new method for screening antidepressants in mice, Psychopharmacology. (Berl.) 85 (1985) 367-370.

- [32] A. Mendiguren, E. Aostri, J. Pineda, Regulation of noradrenergic and serotonergic systems by cannabinoids: relevance to cannabinoid-induced effects, Life. Sci. 192 (2018) 115-127.
- [33] J.M. Franklin, T. Vasiljevik, T.E. Prisinzano, G.A. Carrasco, Cannabinoid 2 receptorand beta Arrestin 2-dependent upregulation of serotonin 2A receptors, Eur.Neuropsychopharmacol. 23 (2013) 760-767.
- [34] G.A. Carrasco, L.D. Van de Kar, Neuroendocrine pharmacology of stress, Eur. J.Pharmacol. 463 (2003) 235-272.
- [35] B.L. Roth, Irving Page Lecture: 5-HT(2A) serotonin receptor biology: interacting proteins, kinases and paradoxical regulation, Neuropharmacology. 61 (2011) 348-354.
- [36] R.M. Concannon, B.N. Okine, D.P. Finn, E. Dowd, Differential upregulation of the cannabinoid CB(2) receptor in neurotoxic and inflammation-driven rat models of Parkinson's disease, Exp. Neurol. 269 (2015) 133-141.
- [37] R.K. Farooq, K. Asghar, S. Kanwal, A. Zulqernain, Role of inflammatory cytokines in depression: Focus on interleukin-1beta, Biomed. Rep. 6 (2017) 15-20.
- [38] J. Paloczi, Z.V. Varga, G. Hasko, P. Pacher, Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation, Antioxid. Redox. Signal. 29 (2018) 75-108.
- [39] J.W. Huffman, J. Liddle, S. Yu, M.M. Aung, M.E. Abood, J.L. Wiley, B.R. Martin, 3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor, Bioorg. Med. Chem. 7 (1999) 2905-2914.
- [40] D. Bolognini, M.G. Cascio, D. Parolaro, R.G. Pertwee, AM630 behaves as a protean ligand at the human cannabinoid CB2 receptor, Br. J.Pharmacol. 165 (2012) 2561-2574.
- [41] I. Smaga, M. Zaniewska, D. Gawlinski, A. Faron-Gorecka, P. Szafranski, M. Cegla, M. Filip, Changes in the cannabinoids receptors in rats following treatment with antidepressants, Neurotoxicology. 63 (2017) 13-20.

Figure legends

Fig. 1. Effect of a combined intraperitoneal administration of JWH133 and antidepressant drugs in (A) the FST and (B) the TST in mice.

Imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) were injected 60 min before testing, whereas JWH133 (0.25 mg/kg) was given 30 min before the experiment. The values represent mean + SEM (n=7-8 mice per group). ^^p<0.01, ^^^p<0.01 versus respective antidepressant drug; ***p<0.001 versus JWH133 (two-way ANOVA followed by Bonferroni's *post-hoc* test).





Fig. 2. Effect of a combined intraperitoneal administration of AM630 and antidepressant drugs in (A) the FST and (B) the TST in mice.

Imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) were injected 60 min before testing, whereas AM630 (0.25 mg/kg) was given 30 min before the experiment. The values represent mean + SEM (n=7-8 mice per group). p <0.01, p <0.01 versus respective antidepressant drug; ***p<0.001 versus AM630 (two-way ANOVA followed by Bonferroni's *post-hoc* test).



	Treatment	Travelled distance (cm)		
(A)	vehicle + vehicle	474.4 ± 49.66		
	JWH133 + vehicle	400.6 ± 51.81		
	imipramine + vehicle	365.0 ± 46.23		
	imipramine + JWH133	517.4 ± 87.69		
	reboxetine + vehicle	310.0 ± 55.38		
	reboxetine + JWH133	418.4 ± 55.94		
(B)	vehicle + vehicle	613.0 ± 48.68		
	JWH133 + vehicle	597.6 ± 50.41		
escitalopram + vehicle		777.4 ± 78.87		
	escitalopram + JWH133	784.87 ± 47.74		
(C)	vehicle + vehicle	526.0 ± 41.97		
	AM630 + vehicle	572.5 ± 48.02		
imipramine + vehicle		559.6 ± 66.81		
	imipramine + AM630	562.7 ± 38.49		
	escitalopram + vehicle	667.9 ± 63.89		
	escitalopram + AM630	818.3 ± 41.97		
(D)	vehicle + vehicle	518.5 ± 68.85		
	AM630 + vehicle	388.4 ± 53.41		
	reboxetine + vehicle	366.4 ± 54.92		
	reboxetine + AM630	432.5 ± 17.95		

Table 1. Effect of a combined intraperitoneal administration of (A, B) JWH133 or (C,D) AM630 and antidepressant drugs on the spontaneous locomotor activity of mice

Imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) were injected 60 min before testing, whereas JWH133 (0.25 mg/kg) and AM630 (0.25 mg/kg) were given 30 min before the experiment. The values represent mean + SEM (n=7-8 mice per group). Two-way ANOVA was used for statistical analysis.

Treatment		Drug/metabolite level in the brain (ng/g)	Treatment	Drug/metabolite level in the brain (ng/g)
imipramine	+	imipramine level	imipramine + vehicle	imipramine level
vehicle		$\textbf{22407} \pm \textbf{3021}$	imipramine + AM630	5358 ± 1098
imipramine	+	$\textbf{18011} \pm \textbf{1654}$		5989 ± 1525
JWH133		desipramine level		desipramine level
		$\textbf{2118} \pm \textbf{484.4}$		441.3 ± 74.48
		$\textbf{1720} \pm \textbf{386.9}$		430.0 ± 70.79
escitalopram	+	escitalopram level	escitalopram +	escitalopram level
vehicle		$\textbf{507.1} \pm \textbf{46.28}$	vehicle	88.89 ± 18.40
escitalopram	+	430.5 ± 91.96	escitalopram +	70.84 ± 11.51
JWH133			AM630	
reboxetine	+	reboxetine level	reboxetine + vehicle	reboxetine level
vehicle		51.49 ± 6.134	reboxetine + AM630	54.95 ± 6.298
reboxetine	+	52.48 ± 7.348		54.90 ± 7.158
JWH133				

Table 2. Effect of JWH133 and AM630 on the brain levels of antidepressants in mice

Imipramine (15 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg) were injected 60 min before testing, whereas JWH133 (5 mg/kg) and AM630 (0.25 mg/kg) were given 30 min before decapitation. The values represent mean \pm SEM (n=6-8 mice per group). *t*-test was used for statistical analysis.